APA (7th ed.) Citation

Matsubara, N., Miyake, H., Uemura, H., Mizokami, A., Kikukawa, H., Kosaka, T., . . . Uemura, H. Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis. Wiley.

Chicago Style (17th ed.) Citation

Matsubara, Nobuaki, et al. Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis. Wiley.

MLA (9th ed.) Citation

Matsubara, Nobuaki, et al. Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis. Wiley.